LOUISVILLE, Ky. -- A CD70-targeted CAR T-cell therapy for advanced kidney cancer continued to show durable activity in ...

As cancer cells grow, they pump out metabolic byproducts such as lactic acid into the tumor microenvironment. Exhausted T ...

An obvious next step in the development and growth of CAR T-cell therapies has been the jump to solid tumors. Because of ...

Researchers say study offers proof-of-concept that targeting how T cells interact with metabolites in their environment can ...

The FDA approved obecabtagene autoleucel (obe-cel; Aucatzyl) for treating relapsed or refractory B-cell precursor acute ...

SYNC, its first homegrown CAR-T therapy, one of the first to show promise in treating certain types of brain cancers. This ...

As cancer cells grow, they pump out metabolic byproducts such as lactic acid into the tumor microenvironment. Exhausted T cells -; which have lost their cancer-fighting oomph -; consume this lactic ...

Discover five T cell engager companies that have emerged in recent times, as this class of therapeutics is set to take off.

A2 Bio shares clinical study progress and the increased diversity of participants in the BASECAMP-1 prescreening study during the SITC annual meeting.

Membraneless organelles, also called biomolecular condensates, are changing how scientists think about protein chemistry, ...

The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based ...